Advice
following a full submission:
testosterone undecanoate (Nebido) is accepted for use within NHSScotland as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.
Compared with alternative intramuscular preparations it offers the advantage of reduced frequency of dosing with less inter-dose fluctuation of testosterone levels.
Download detailed advice83KB (PDF)
Medicine details
- Medicine name:
- testosterone undecanoate (Nebido)
- SMC ID:
- 308/06
- Indication:
- as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 March 2009